Anthrax

Anthrax vaccine candidate receives fast track designation

Published in Vaccine Weekly, February 18th, 2004

VaxGen, Inc., (VXGN) announced that the U.S. Food and Drug Administration (FDA) has granted a Fast Track designation to the company's anthrax vaccine candidate, rPA102.

The Fast Track designation means that FDA will take such actions that are appropriate to expedite the development and review of a license application for rPA102, when and if it is submitted to the FDA.

Under the FDA Modernization Act of 1997, the FDA's Fast Track Program is designed to expedite the development and review of a new drug that is intended for the treatment or prevention of a serious or life-threatening condition, and demonstrates the potential of a drug candidate to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-02-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry